By a News Reporter-Staff News Editor at Life Science Weekly -- Current study results on Gram-Positive Bacteria - Clostridium difficile have been published. According to news reporting originating in Belgrade, Serbia, by NewsRx journalists, research stated, “The aim of this study was to compare clinical cure rate, recurrence rate and time to resolution of diarrhea in patients with severe and severe-complicated Clostridium difficile infection (CDI) treated with teicoplanin or vancomycin. This two-year prospective observational study included patients with first episode or first recurrence of CDI who had severe or severe-complicated CDI and were treated with teicoplanin or vancomycin.”
The news reporters obtained a quote from the research from the University of Belgrade, “Primary outcomes of interest were clinical cure rate at discharge and recurrence rate after eight weeks follow up, and secondary outcomes were all-cause mortality and time to resolution of diarrhea. Among 287 study patients, 107 were treated with teicoplanin and 180 with vancomycin. The mean age of patients was 73.5 +/- 10.6 years. One hundred eighty six patients (64.8%) had prior CDI episode. Severe complicated disease was detected in 23/107 (21.5%) and 42/180 (23.3%) patients treated with teicoplanin and vancomycin, respectively. There was no statistically significant difference in time to resolution of diarrhea between two treatment arms (6.0 +/- 3.4 vs 6.2 +/- 3.1 days, p = 0.672). Treatment with teicoplanin resulted in significantly higher clinical cure rate compared to vancomycin [90.7% vs 79.4%, p = 0.013, odds ratio (OR) (95% confidence interval (CI)) 2.51 (1.19-5.28)]. Recurrence rates were significantly lower in patients treated with teicoplanin [9/97 (9.3%) vs 49/143 (34.3%), p< 0.001, OR (95%CI) 0.20 (0.09-0.42)]. There was no statistically significant difference in overall mortality rate. Teicoplanin might be a good treatment option for patients with severe CDI.”
According to the news reporters, the research concluded: “Patients treated with teicoplanin experienced remarkably lower recurrence rates compared to vancomycin-treated patients.”
For more information on this research see: Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. European Journal of Clinical Microbiology & Infectious Diseases , 2018;37(4):745-754. European Journal of Clinical Microbiology & Infectious Diseases can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; European Journal of Clinical Microbiology & Infectious Diseases - http://www.springerlink.com/content/0934-9723/)
Our news correspondents report that additional information may be obtained by contacting I. Milosevic, University of Belgrade, Sch Med, Belgrade, Serbia. Additional authors for this research include M. Korac, Z. Nesic, B. Milosevic, A. Urosevic, D. Jevtovic, N. Mitrovic, A. Markovic, J. Jordovic, N. Katanic, A. Barac and N. Popovic.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s10096-017-3169-3. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-04-24), Findings from University of Belgrade Yields New Data on Clostridium difficile (Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study), Life Science Weekly, 2469, ISSN: 1552-2474, BUTTER® ID: 015538005
From the newsletter Life Science Weekly.
https://www.newsrx.com/Butter/#!Search:a=15538005
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.